Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (Q34098866)

31 July 2017

1 reference

title

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (English)

1 reference

31 July 2017

0 references

0 references

0 references

4

Henrik Zetterberg

1 reference

31 July 2017

2

Harald Hampel

1 reference

31 July 2017

1

Kaj Blennow

1 reference

31 July 2017

3

Michael Weiner

1 reference

PubMed ID

20157306

31 July 2017

language of work or name

English

0 references

publication date

16 February 2010

1 reference

31 July 2017

Nature Reviews Neurology

1 reference

31 July 2017

6

1 reference

31 July 2017

131-144

1 reference

31 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.4

31 July 2017

0 references

cites work

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Aging and Alzheimer's disease: lessons from the Nun Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Distribution of tau proteins in the normal human central and peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Tau pathology in Alzheimer disease and other tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Amyloid plaque core protein in Alzheimer disease and Down syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

How can we recognize "disease modification" effects?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

PET imaging of amyloid deposition in patients with mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Neurochemical aftermath of amateur boxing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Both total and phosphorylated tau are increased in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid markers for prediction of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF markers for incipient Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Frontotemporal dementia: clinicopathological correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Lewy Body Pathology in Alzheimer's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The neuropathology of probable Alzheimer disease and mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Biochemical markers in persons with preclinical familial Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF biomarkers in frontotemporal lobar degeneration with known pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

A novel pathway for amyloid precursor protein processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

A beta oligomers - a decade of discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Autoantibodies to amyloid-beta and Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Identification of novel brain biomarkers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Use of biomarkers in Alzheimer's trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Biomarkers of Alzheimer disease in plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Proteome-based plasma biomarkers for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Markers of Alzheimer's disease in a population attending a memory clinic.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Presenilin: running with scissors in the membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Amyloid beta-peptide is produced by cultured cells during normal metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Tau protein and the neurofibrillary pathology of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Uses and abuses of screening tests

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Cholinesterase inhibitors for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.4

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values

31 March 2020

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Selective Reductions in Plasma A 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report

1 reference

12 December 2020

Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer.

1 reference

12 December 2020

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors

1 reference

12 December 2020

Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing.

1 reference

12 December 2020

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2010.4

1 reference

PubMed ID

20157306

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

20157306